1. Home
  2. LGCL vs MCRB Comparison

LGCL vs MCRB Comparison

Compare LGCL & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGCL
  • MCRB
  • Stock Information
  • Founded
  • LGCL 2009
  • MCRB 2010
  • Country
  • LGCL China
  • MCRB United States
  • Employees
  • LGCL N/A
  • MCRB N/A
  • Industry
  • LGCL
  • MCRB Biotechnology: Pharmaceutical Preparations
  • Sector
  • LGCL
  • MCRB Health Care
  • Exchange
  • LGCL NYSE
  • MCRB Nasdaq
  • Market Cap
  • LGCL 119.4M
  • MCRB 103.7M
  • IPO Year
  • LGCL 2024
  • MCRB 2015
  • Fundamental
  • Price
  • LGCL $0.83
  • MCRB $14.53
  • Analyst Decision
  • LGCL
  • MCRB Hold
  • Analyst Count
  • LGCL 0
  • MCRB 4
  • Target Price
  • LGCL N/A
  • MCRB $73.67
  • AVG Volume (30 Days)
  • LGCL 179.0K
  • MCRB 164.6K
  • Earning Date
  • LGCL 01-01-0001
  • MCRB 08-06-2025
  • Dividend Yield
  • LGCL N/A
  • MCRB N/A
  • EPS Growth
  • LGCL N/A
  • MCRB N/A
  • EPS
  • LGCL 0.07
  • MCRB 8.98
  • Revenue
  • LGCL $145,690,427.00
  • MCRB N/A
  • Revenue This Year
  • LGCL N/A
  • MCRB N/A
  • Revenue Next Year
  • LGCL N/A
  • MCRB N/A
  • P/E Ratio
  • LGCL $12.12
  • MCRB $1.74
  • Revenue Growth
  • LGCL N/A
  • MCRB N/A
  • 52 Week Low
  • LGCL $0.28
  • MCRB $6.53
  • 52 Week High
  • LGCL $3.31
  • MCRB $29.40
  • Technical
  • Relative Strength Index (RSI)
  • LGCL N/A
  • MCRB 66.40
  • Support Level
  • LGCL N/A
  • MCRB $11.15
  • Resistance Level
  • LGCL N/A
  • MCRB $14.78
  • Average True Range (ATR)
  • LGCL 0.00
  • MCRB 1.38
  • MACD
  • LGCL 0.00
  • MCRB -0.05
  • Stochastic Oscillator
  • LGCL 0.00
  • MCRB 72.33

About LGCL LUCAS GC LIMITED

Lucas GC Ltd is a technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China. Its business segments consist of recruitment services, outsourcing services, and other services, which include information technology services and training services.

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Share on Social Networks: